心脏手术中的抗纤溶治疗。
Antifibrinolytic therapy in cardiac surgery.
作者信息
Chen R H, Frazier O H, Cooley D A
机构信息
Department of Cardiovascular Surgery, Texas Heart Institute, Houston 77030, USA.
出版信息
Tex Heart Inst J. 1995;22(3):211-5.
Abstract
Bleeding remains an important complication after repeat and complicated cardiac surgery. Although aprotinin has recently been approved by the Food and Drug Administration for use as an antifibrinolytic agent, many surgeons continue to have concerns about its added cost and potential side effects. We review here the current state of antifibrinolytic therapy for excessive bleeding in cardiothoracic surgery and suggest the use of a single intravenous dose of 10 g of epsilon-aminocaproic acid immediately before cardiopulmonary bypass as a safe, inexpensive, and effective alternative to aprotinin. Further clinical and laboratory studies are needed to confirm or modify this protocol.
摘要
在再次心脏手术和复杂心脏手术后，出血仍然是一个重要的并发症。尽管抑肽酶最近已获美国食品药品监督管理局批准用作抗纤溶药物，但许多外科医生仍对其增加的成本和潜在副作用感到担忧。我们在此回顾心胸外科手术中针对过度出血的抗纤溶治疗现状，并建议在体外循环前立即静脉注射单次剂量10克的ε-氨基己酸，作为抑肽酶的一种安全、廉价且有效的替代方法。需要进一步的临床和实验室研究来证实或修改该方案。
相似文献
1
Antifibrinolytic therapy in cardiac surgery.心脏手术中的抗纤溶治疗。
Tex Heart Inst J. 1995;22(3):211-5.
2
3
Coronary artery bypass grafting after aprotinin: are we doing better?抑肽酶后行冠状动脉旁路移植术：我们做得更好了吗？
J Thorac Cardiovasc Surg. 2013 Jan;145(1):243-8. doi: 10.1016/j.jtcvs.2012.09.032. Epub 2012 Oct 13.
4
The use of low-dose aprotinin, epsilon-aminocaproic acid or tranexamic acid for prevention of mediastinal bleeding in patients receiving aspirin before coronary artery bypass operations.在冠状动脉搭桥手术前接受阿司匹林治疗的患者中，使用低剂量抑肽酶、ε-氨基己酸或氨甲环酸预防纵隔出血。
Eur J Cardiothorac Surg. 1997 Apr;11(4):798-800. doi: 10.1016/s1010-7940(96)01126-8.
5
Antifibrinolytic therapy during cardiopulmonary bypass reduces proinflammatory cytokine levels: a randomized, double-blind, placebo-controlled study of epsilon-aminocaproic acid and aprotinin.体外循环期间抗纤溶治疗可降低促炎细胞因子水平：一项关于ε-氨基己酸和抑肽酶的随机、双盲、安慰剂对照研究。
J Thorac Cardiovasc Surg. 2003 Nov;126(5):1498-503. doi: 10.1016/s0022-5223(03)00946-2.
6
Is epsilon-aminocaproic acid as effective as aprotinin in reducing bleeding with cardiac surgery?: a meta-analysis.ε-氨基己酸在减少心脏手术出血方面与抑肽酶效果相同吗？一项荟萃分析。
Circulation. 1999;99(1):81-9. doi: 10.1161/01.cir.99.1.81.
7
The safety of aprotinin and lysine-derived antifibrinolytic drugs in cardiac surgery: a meta-analysis.抑肽酶和赖氨酸衍生的抗纤溶药物在心脏手术中的安全性：一项荟萃分析。
CMAJ. 2009 Jan 20;180(2):183-93. doi: 10.1503/cmaj.081109. Epub 2008 Dec 2.
8
The effect of antifibrinolytic prophylaxis on postoperative outcomes in patients undergoing cardiac operations.抗纤维蛋白溶解预防措施对心脏手术患者术后结局的影响。
Int Surg. 2012 Jan-Mar;97(1):34-42. doi: 10.9738/CC75.1.
9
Removal of aprotinin from low-dose aprotinin/tranexamic acid antifibrinolytic therapy increases transfusion requirements in cardiothoracic surgery.在心胸外科手术中，从低剂量抑肽酶/氨甲环酸抗纤溶治疗方案中去除抑肽酶会增加输血需求。
Interact Cardiovasc Thorac Surg. 2011 Feb;12(2):135-9. doi: 10.1510/icvts.2010.250936. Epub 2010 Nov 12.
10
Efficacy of aprotinin, epsilon aminocaproic acid, or combination in cyanotic heart disease.抑肽酶、ε-氨基己酸或两者联合用于治疗青紫型心脏病的疗效
Ann Thorac Surg. 2000 Oct;70(4):1308-12. doi: 10.1016/s0003-4975(00)01752-5.
引用本文的文献
1
Epsilon aminocaproic acid reduces blood transfusion and improves the coagulation test after pediatric open-heart surgery: a meta-analysis of 5 clinical trials.ε-氨基己酸可减少小儿心脏直视手术后的输血并改善凝血试验：5项临床试验的荟萃分析
Int J Clin Exp Pathol. 2015 Jul 1;8(7):7978-87. eCollection 2015.
2
Methods for improved hemorrhage control.改善出血控制的方法。
Crit Care. 2004;8 Suppl 2(Suppl 2):S57-60. doi: 10.1186/cc2407. Epub 2004 Jun 14.
本文引用的文献
1
Problems in hemostasis during openheart surgery. III. Epsilon amino caproic acid as an inhibitor of plasminogen activator activity.心脏直视手术中的止血问题。III. ε-氨基己酸作为纤溶酶原激活物活性的抑制剂
Ann Surg. 1962 Feb;155(2):268-76. doi: 10.1097/00000658-196200000-00017.
2
The mechanism of clot dissolution by plasmin.纤溶酶溶解血栓的机制。
J Clin Invest. 1959 Jul;38(7):1086-95. doi: 10.1172/JCI103885.
3
Blood-surface interactions during cardiopulmonary bypass.体外循环期间的血液-表面相互作用。
J Card Surg. 1993 May;8(3):404-10. doi: 10.1111/j.1540-8191.1993.tb00384.x.
4
Tranexamic acid (Cyklokapron) is not necessary to reduce blood loss after coronary artery bypass operations.
J Thorac Cardiovasc Surg. 1993 Jan;105(1):78-83.
5
Decreased postoperative drainage with addition of epsilon-aminocaproic acid before cardiopulmonary bypass.在体外循环前添加ε-氨基己酸可减少术后引流。
Ann Thorac Surg. 1994 May;57(5):1108-12; discussion 1112-3. doi: 10.1016/0003-4975(94)91338-2.
6
Effect of prophylactic epsilon-aminocaproic acid on blood loss and transfusion requirements in patients undergoing first-time coronary artery bypass grafting. A randomized, prospective, double-blind study.
J Thorac Cardiovasc Surg. 1994 Jul;108(1):99-106; discussion 106-8.
7
The platelet function defect of cardiopulmonary bypass.体外循环的血小板功能缺陷
Blood. 1993 Jul 1;82(1):107-17.
8
Aprotinin in perspective.抑肽酶的前景
Ann Thorac Surg. 1993 Apr;55(4):1033-41. doi: 10.1016/0003-4975(93)90149-c.
9
Metaanalysis of prophylactic drug treatment in the prevention of postoperative bleeding.预防性药物治疗预防术后出血的荟萃分析。
Ann Thorac Surg. 1994 Dec;58(6):1580-8. doi: 10.1016/0003-4975(94)91636-5.
10
Aprotinin significantly decreases bleeding and transfusion requirements in patients receiving aspirin and undergoing cardiac operations.
J Thorac Cardiovasc Surg. 1994 Feb;107(2):554-61.
Zotero 插件